"Pharmaceutical Representative Licensing Act."

This bill (A 538, "Pharmaceutical Representative Licensing Act") requires all individuals marketing pharmaceuticals to healthcare practitioners in New Jersey to obtain a state license. It directly affects pharmaceutical sales representatives, who must meet education, ethics, and background requirements, complete biennial continuing education (including opioid safety training), and report all interactions with doctors - including promoted drugs, samples given, and gifts provided. The State Board of Medical Examiners will oversee licensing, enforce standards (like banning deceptive marketing or false medical credentials), and may suspend licenses for violations. The bill aims to increase transparency and professionalism in pharmaceutical sales interactions.